CN105829304A - N,n’取代哌啶胺类化合物、其制备方法及用途 - Google Patents

N,n’取代哌啶胺类化合物、其制备方法及用途 Download PDF

Info

Publication number
CN105829304A
CN105829304A CN201480069570.4A CN201480069570A CN105829304A CN 105829304 A CN105829304 A CN 105829304A CN 201480069570 A CN201480069570 A CN 201480069570A CN 105829304 A CN105829304 A CN 105829304A
Authority
CN
China
Prior art keywords
methyl
piperidin
amine
methoxypyrimidin
cyanobenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201480069570.4A
Other languages
English (en)
Other versions
CN105829304B (zh
Inventor
钟武
李松
曾燕群
肖军海
周辛波
郑志兵
李行舟
王晓奎
***
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Publication of CN105829304A publication Critical patent/CN105829304A/zh
Application granted granted Critical
Publication of CN105829304B publication Critical patent/CN105829304B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及式(I)的化合物、其立体异构体、可药用盐、溶剂化物或N‑氧化物，包含所述化合物的药物组合物，所述化合物的制备方法，以及所述化合物用于治疗与Hsp70有关的疾病中的用途，其中所述疾病优选选自肿瘤、神经退行性疾病、异源移植的排斥和感染。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201480069570.4A 2013-12-20 2014-12-19 N,n’取代哌啶胺类化合物、其制备方法及用途 Active CN105829304B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013107047593 2013-12-20
CN201310704759 2013-12-20
PCT/CN2014/094338 WO2015090226A1 (zh) 2013-12-20 2014-12-19 N，n'取代哌啶胺类化合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
CN105829304A true CN105829304A (zh) 2016-08-03
CN105829304B CN105829304B (zh) 2019-09-20

Family

ID=53402123

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480069570.4A Active CN105829304B (zh) 2013-12-20 2014-12-19 N,n’取代哌啶胺类化合物、其制备方法及用途

Country Status (4)

Country Link
US (1) US10023565B2 (zh)
EP (1) EP3085701B1 (zh)
CN (1) CN105829304B (zh)
WO (1) WO2015090226A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829293A (zh) * 2013-12-20 2016-08-03 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230303512A1 (en) * 2020-08-26 2023-09-28 Massachusetts Institute Of Technology Modulators of myb-mediated transcription and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514398A (en) * 1982-03-30 1985-04-30 Adir Disubstituted polymethylene imines
EP0156433A2 (en) * 1984-03-26 1985-10-02 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US5260318A (en) * 1990-10-16 1993-11-09 Basf Aktiengesellschaft Phenylpiperidylamines and drugs containing them
CN1195348A (zh) * 1995-07-07 1998-10-07 曼海姆泊灵格股份公司 新的噁唑烷酮衍生物,它们的制备方法和含有这些化合物的药剂
CN1777612A (zh) * 2003-03-31 2006-05-24 普雷迪克医药品控股公司 新的哌啶基氨基－噻吩并[2,3－d]嘧啶化合物
WO2009106561A1 (en) * 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2012166617A2 (en) * 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514398A (en) * 1982-03-30 1985-04-30 Adir Disubstituted polymethylene imines
EP0156433A2 (en) * 1984-03-26 1985-10-02 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US5260318A (en) * 1990-10-16 1993-11-09 Basf Aktiengesellschaft Phenylpiperidylamines and drugs containing them
CN1195348A (zh) * 1995-07-07 1998-10-07 曼海姆泊灵格股份公司 新的噁唑烷酮衍生物,它们的制备方法和含有这些化合物的药剂
CN1777612A (zh) * 2003-03-31 2006-05-24 普雷迪克医药品控股公司 新的哌啶基氨基－噻吩并[2,3－d]嘧啶化合物
WO2009106561A1 (en) * 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2012166617A2 (en) * 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALAIN DHAINAUT，等: "New Purines and Purine Analogs as Modulators of Multidrug Resistance", 《J. MED. CHEM.》 *
DATABASE REAXYS: "No.6869503、6871206、6875045", 《DATABASE REAXYS》 *
JIANMIN JIA，等: "Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening", 《PLOS ONE》 *
MARISSA V. POWERS，等: "Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone?", 《CELL CYCLE》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829293A (zh) * 2013-12-20 2016-08-03 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途
US9840489B2 (en) 2013-12-20 2017-12-12 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Piperidine carboxamide compound, preparation method, and usage thereof
US10301279B2 (en) 2013-12-20 2019-05-28 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Piperidine carboxamide compound, preparation method, and use thereof
US11447463B2 (en) 2013-12-20 2022-09-20 Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. China Piperidine carboxamide compound, preparation method, and use thereof

Also Published As

Publication number Publication date
US10023565B2 (en) 2018-07-17
WO2015090226A1 (zh) 2015-06-25
EP3085701A1 (en) 2016-10-26
US20160333002A1 (en) 2016-11-17
EP3085701B1 (en) 2019-02-20
EP3085701A4 (en) 2017-10-18
CN105829304B (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
JP7035108B2 (ja) プリドピジンの類似体、それらの製造および使用
JP7042812B2 (ja) トリアゾロピリミジン化合物の結晶形態
EP3464292B1 (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
TW201408661A (zh) 抗病毒性化合物之固體形式
CN110759908B (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
TW201726637A (zh) 對電位閘控鈉通道具選擇活性之羥基烷基胺－及羥基環烷基胺－取代之二胺－芳基磺胺化合物
JP2021528470A (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
CN113993519A (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
JP7397452B2 (ja) ヘテロアリールカルボキシアミド化合物
EP3781567B1 (en) Imidazopyridines useful as mitochondrial uncouplers
EP3630115A1 (en) Compositions and methods for preparing and using mitochondrial uncouplers
RU2648242C2 (ru) Производное имидазопиридина, используемое для лечения сахарного диабета
KR20180085814A (ko) 치환된 5,6-디히드로-6-페닐벤조[f]이소퀴놀린-2-아민의 제조 방법
CN105829304A (zh) N,n’取代哌啶胺类化合物、其制备方法及用途
WO2018059533A1 (zh) p38αMAPK激酶抑制剂及其制备方法和应用
TW470645B (en) Compound for inhibiting or preventing HIV infection, its preparation and pharmaceutical composition comprising same
KR20220134747A (ko) 벤젠고리 함유 화합물 및 이의 적용
EP3663299A1 (en) Bicyclic compound acting as ror inhibitor
US20080139608A1 (en) 2,6,8, Trisubstituted 1-deazapurines and their different uses
EP4155304A1 (en) Compound used as ret kinase inhibitor and application thereof
US11447463B2 (en) Piperidine carboxamide compound, preparation method, and use thereof
EP3085690A1 (en) New urea compound, manufacturing method and application thereof
WO2019203951A1 (en) Selective potassium channel agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant